Scholarlink

Purpose <p>Sodium–glucose cotransporter-2 inhibitors are widely used in older adults with type 2 diabetes mellitus; however, their effects on geriatric syndromes remain incompletely understood. This study evaluated the longitudinal effects of dapagliflozin and empagliflozin on older adults using a comprehensive geriatric assessment (CGA).</p> Methods <p>This study included 42 adults aged ≥ 65 years with type 2 diabetes mellitus (dapagliflozin, <i>n</i> = 22; empagliflozin, <i>n</i> = 20). Assessments were performed at baseline and after approximately six months. CGA was a core component of the study and included the FRAIL scale, Mini-Mental State Examination, Timed Up and Go test, gait speed, Tinetti gait and balance assessment, handgrip strength, and the Pittsburgh Sleep Quality Index.</p> Results <p>In the dapagliflozin group, body mass index decreased from 31.0 ± 4.9 to 27.8 ± 4.7&#xa0;kg/m² (<i>p</i> = 0.018), accompanied by reductions in fat-free mass (FFM) (52.75 ± 7.41 to 51.05 ± 6.95&#xa0;kg, <i>p</i> = 0.020) and skeletal muscle mass index (SMMI) (11.68 ± 1.01 to 11.38 ± 0.88&#xa0;kg/m², <i>p</i> = 0.039). In the empagliflozin group, body mass index (BMI) also decreased (32.8 ± 5.5 to 31.6 ± 4.8&#xa0;kg/m², <i>p</i> = 0.013), while SMMI remained stable. A significant time × group interaction was observed for SMMI (<i>p</i> = 0.023). No significant changes were detected in frailty, physical performance, cognitive function, muscle strength, sleep quality, or fall frequency.</p> Conclusion <p>While dapagliflozin was associated with slight muscle mass loss, empagliflozin preserved muscle. Neither drug negatively affected frailty, cognition, physical performance, or sleep. These findings support their safe use in older adults, with attention to individual patient needs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Differential effects of dapagliflozin and empagliflozin on skeletal muscle mass in older adults with type 2 diabetes

  • 期刊论文

  • 发表日期：

    2026年6月2日

查看全文
  • Sencer Ganidagli,
  • Eyüp Sami Akbas,
  • Zeynel Abidin Ozturk

摘要

Purpose

Sodium–glucose cotransporter-2 inhibitors are widely used in older adults with type 2 diabetes mellitus; however, their effects on geriatric syndromes remain incompletely understood. This study evaluated the longitudinal effects of dapagliflozin and empagliflozin on older adults using a comprehensive geriatric assessment (CGA).

Methods

This study included 42 adults aged ≥ 65 years with type 2 diabetes mellitus (dapagliflozin, n = 22; empagliflozin, n = 20). Assessments were performed at baseline and after approximately six months. CGA was a core component of the study and included the FRAIL scale, Mini-Mental State Examination, Timed Up and Go test, gait speed, Tinetti gait and balance assessment, handgrip strength, and the Pittsburgh Sleep Quality Index.

Results

In the dapagliflozin group, body mass index decreased from 31.0 ± 4.9 to 27.8 ± 4.7 kg/m² (p = 0.018), accompanied by reductions in fat-free mass (FFM) (52.75 ± 7.41 to 51.05 ± 6.95 kg, p = 0.020) and skeletal muscle mass index (SMMI) (11.68 ± 1.01 to 11.38 ± 0.88 kg/m², p = 0.039). In the empagliflozin group, body mass index (BMI) also decreased (32.8 ± 5.5 to 31.6 ± 4.8 kg/m², p = 0.013), while SMMI remained stable. A significant time × group interaction was observed for SMMI (p = 0.023). No significant changes were detected in frailty, physical performance, cognitive function, muscle strength, sleep quality, or fall frequency.

Conclusion

While dapagliflozin was associated with slight muscle mass loss, empagliflozin preserved muscle. Neither drug negatively affected frailty, cognition, physical performance, or sleep. These findings support their safe use in older adults, with attention to individual patient needs.